Dermavant Sciences has signed a $160m revenue interest purchase and sale agreement for tapinarof with Marathon Asset Management, NovaQuest Capital Management and a third unnamed institutional investor in the US.
Dermavant Sciences, a subsidiary of Roivant Sciences, has signed an exclusive agreement to sell the development and commercial rights of tapinarof in Japan.